ID   RMG-I
AC   CVCL_1662
SY   RMG1; RMG-1
DR   BTO; BTO:0004930
DR   EFO; EFO_0006746
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471003
DR   BioSample; SAMN10988355
DR   CCLE; RMGI_OVARY
DR   Cell_Model_Passport; SIDM00352
DR   CGH-DB; 336-2
DR   CGH-DB; 9362-4
DR   ChEMBL-Cells; CHEMBL3308778
DR   ChEMBL-Targets; CHEMBL1075564
DR   Cosmic; 909699
DR   Cosmic; 931360
DR   Cosmic; 945377
DR   Cosmic; 1152556
DR   Cosmic; 1223319
DR   Cosmic; 1328068
DR   Cosmic; 1708378
DR   Cosmic; 1889262
DR   Cosmic; 2482708
DR   Cosmic; 2582799
DR   Cosmic-CLP; 909699
DR   DepMap; ACH-000719
DR   GDSC; 909699
DR   GEO; GSM659403
DR   GEO; GSM827210
DR   GEO; GSM887544
DR   GEO; GSM888627
DR   GEO; GSM1001429
DR   GEO; GSM1001430
DR   GEO; GSM1176283
DR   GEO; GSM1670383
DR   GEO; GSM2475004
DR   IARC_TP53; 21289
DR   JCRB; IFO50315
DR   JCRB; JCRB0172
DR   JCRB; FDSC0027
DR   LiGeA; CCLE_443
DR   LINCS_LDP; LCL-1805
DR   PharmacoDB; RMGI_1320_2019
DR   Wikidata; Q54950664
RX   CelloPub=CLPUB00481;
RX   PubMed=3154025;
RX   PubMed=8980248;
RX   PubMed=11330945;
RX   PubMed=12417041;
RX   PubMed=17671176;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=22705003;
RX   PubMed=23430509;
RX   PubMed=23839242;
RX   PubMed=24023729;
RX   PubMed=25485619;
RX   PubMed=25846456;
RX   PubMed=25960936;
RX   PubMed=25984343;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=28273451;
RX   PubMed=30485824;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   http://tcpaportal.org/mclp/
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 60 hours (PubMed=3154025); 40 hours (PubMed=25984343); ~30 hours (lot 07052011), ~31 hours (lot 07142017), ~72 hours (lot 1225201) (JCRB).
CC   HLA typing: A*24:02,24:02; B*40:02,40:02; C*03:04,03:04 (PubMed=25960936).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Homozygous for CDKN2A deletion (PubMed=8980248).
CC   Sequence variation: CDKN2A p.Arg58Arg (c.174A>C) (p.Ser73Arg; c.217A>C) (PubMed=25846456).
CC   Sequence variation: TERT c.228C>T (-124C>T); in promoter (PubMed=31068700).
CC   Sequence variation: Has no TP53 mutation (CCLE; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0.61%; East Asian, North=81.67%; East Asian, South=17.3%; South Asian=0%; European, North=0.42%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; FDSC0027; true.
CC   Derived from metastatic site: Ascites.
ST   Source(s): Cosmic-CLP; JCRB; PubMed=25877200; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 8,12
ST   D16S539: 9,10
ST   D18S51: 13,15
ST   D21S11: 29,30
ST   D3S1358: 15,16
ST   D5S818: 12
ST   D7S820: 11
ST   D8S1179: 15,16
ST   FGA: 25,26
ST   Penta D: 9,10
ST   Penta E: 15,16
ST   TH01: 6,7
ST   TPOX: 11
ST   vWA: 17,18
DI   NCIt; C40078; Ovarian clear cell adenocarcinoma
DI   ORDO; Orphanet_398971; Clear cell adenocarcinoma of the ovary
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   34Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 27
//
RX   CelloPub=CLPUB00481;
RA   Kuno H., Yoshida T.;
RT   "Detection of human papillomavirus types 16, 18, and 33 in cell lines
RT   derived from human genital organs by polymerase chain reaction.";
RL   Res. Commun. Inst. Ferment. Osaka 18:6-12(1997).
//
RX   PubMed=3154025;
RA   Nozawa S., Tsukazaki K., Sakayori M., Jeng C.H., Iizuka R.;
RT   "Establishment of a human ovarian clear cell carcinoma cell line (RMG-I)
RT   and its single cell cloning -- with special reference to the stem cell
RT   of the tumor.";
RL   Hum. Cell 1:426-435(1988).
//
RX   PubMed=8980248; DOI=10.1002/(SICI)1097-0215(19961220)69:6<466::AID-IJC8>3.0.CO;2-2;
RA   Ichikawa Y., Yoshida S., Koyama Y., Hirai M., Ishikawa T., Nishida M.,
RA   Tsunoda H., Kubo T., Miwa M., Uchida K.;
RT   "Inactivation of p16/CDKN2 and p15/MTS2 genes in different
RT   histological types and clinical stages of primary ovarian tumors.";
RL   Int. J. Cancer 69:466-470(1996).
//
RX   PubMed=11330945; DOI=10.1006/gyno.2001.6132;
RA   Watanabe T., Imoto I., Kosugi Y., Ishiwata I., Inoue S., Takayama M.,
RA   Sato A., Inazawa J.;
RT   "A novel amplification at 17q21-23 in ovarian cancer cell lines
RT   detected by comparative genomic hybridization.";
RL   Gynecol. Oncol. 81:172-177(2001).
//
RX   PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x;
RA   Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M.,
RA   Takayama M., Sato A., Inazawa J.;
RT   "Differentially regulated genes as putative targets of amplifications
RT   at 20q in ovarian cancers.";
RL   Jpn. J. Cancer Res. 93:1114-1122(2002).
//
RX   PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567;
RA   Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K.,
RA   Hirohashi S., Inazawa J., Imoto I.;
RT   "Promoter hypermethylation contributes to frequent inactivation of a
RT   putative conditional tumor suppressor gene connective tissue growth
RT   factor in ovarian cancer.";
RL   Cancer Res. 67:7095-7105(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22705003; DOI=10.1016/j.humpath.2012.03.011;
RA   Rahman M., Nakayama K., Rahman M.T., Nakayama N., Ishikawa M.,
RA   Katagiri A., Iida K., Nakayama S., Otsuki Y., Shih I.-M.,
RA   Miyazaki K.;
RT   "Clinicopathologic and biological analysis of PIK3CA mutation in
RT   ovarian clear cell carcinoma.";
RL   Hum. Pathol. 43:2197-2206(2012).
//
RX   PubMed=23430509; DOI=10.1007/s13577-013-0062-y;
RA   Itamochi H., Kato M., Nishimura M., Oumi N., Oishi T., Shimada M.,
RA   Sato S., Naniwa J., Sato S., Nonaka M., Kudoh A., Terakawa N.,
RA   Kigawa J., Harada T.;
RT   "Establishment and characterization of a novel ovarian clear cell
RT   adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA
RT   gene.";
RL   Hum. Cell 26:121-127(2013).
//
RX   PubMed=23839242; DOI=10.1038/ncomms3126;
RA   Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.;
RT   "Evaluating cell lines as tumour models by comparison of genomic
RT   profiles.";
RL   Nat. Commun. 4:2126-2126(2013).
//
RX   PubMed=24023729; DOI=10.1371/journal.pone.0072162;
RA   Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M.,
RA   Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R.,
RA   Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.;
RT   "Type-specific cell line models for type-specific ovarian cancer
RT   research.";
RL   PLoS ONE 8:E72162-E72162(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25846456; DOI=10.3892/ijo.2015.2951;
RA   Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M.,
RA   Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.;
RT   "Profiling of actionable gene alterations in ovarian cancer by
RT   targeted deep sequencing.";
RL   Int. J. Oncol. 46:2389-2398(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:E954893-E954893(2014).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P., Novak M., Doodnauth S.A.,
RA   Saiz F.S., Cullis J., Al-Awar R., Neel B.G., McPherson J., Drapkin R.,
RA   Ailles L., Mes-Massons A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R., Easwaran H., Baylin S.B., Slamon D.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//